MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

Cancer Research

Volumn 71, Issue 2, 2011, Pages 445-453

  Yoon, Juyong ^a   Koo, Kyoung Hwa ^a   Choi, Kang Yell ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AS 703026; CETUXIMAB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PROTEIN SERINE THREONINE KINASE INHIBITOR; SELUMETINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CELL MUTANT; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; BENZIMIDAZOLES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NIACINAMIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751480476     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3058     Document Type: Article

References (47)

1. Sung JJ, Lau JY,Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005;6:871-6.
2. Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC. Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol 2009;24:1810-6.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-42.
6. Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med 2009;360:623-5.
7. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
9. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9.
10. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
11. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
13. August J. Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov 2010;9:351.
14. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
15. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4:373-84.
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
17. Downward J. Targeting RAS and PI3K in lung cancer. Nat Med 2008;14:1315-6.
18. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005;386:193-205.
19. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.
20. Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, openlabel, randomised study to assess the efficacy and safety of the MEK1/ 2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs Epub 2010 Feb 2.
21. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010;3:8.
22. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15.
23. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6.
24. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.
25. Drummer R, Robert C, Chapman P, Sosman J, Middleton M, Bastholt L, et al. AZD6244 (ARRY-142886) vs Temozolomide in Patients With Advanced Melanoma: an Open-Label, Randomized, Multicenter, Phase II Study [abstract]. J Clin Oncol 2008;26:9033.
26. O'Neil BH, Williams-Goff LW, Kauh J, Bekaii-Saab T, Strosberg JR, Lee R, et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma [abstract]. J Clin Oncol 2009;27:15574.
27. Lang I, Adenis A, Boer K, Escudero P, Kim T, Valladares M, et al. AZD6244 (ARRY-142886) Versus capecitabine in patients with metastatic colorectal cancer who have failed prior chemotherapy [abstract]. J Clin Oncol 2008;26:4114.
28. Tzekova V, Cebotaru C, Ciuleanu TE, Damjanov D, Ganchev V, Kanarev V, et al. Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced nonsmall cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008;28:8029.
29. Price S. Putative allosteric MEK1 and MEK2 inhibitors. Expert Opin Ther Patents 2008;18:603-27.
30. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010;149:537-49.
31. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
32. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
33. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009;106:18351-6.
34. Waters SB, Holt KH, Ross SE, Syu LJ, Guan KL, Saltiel AR, et al. Desensitization of Ras activation by a feedback disassociation of the SOS-Grb2 complex. J Biol Chem 1995;270:20883-6.
35. Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM. Negative feedback regulation and desensitization of insulin- and epidermal growth factorstimulated p21ras activation. J Biol Chem 1995;270:25320-3.
36. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
37. Ferro E, Trabalzini L. RalGDS family members couple Ras to Ral signalling and that's not all. Cell Signal 2010;22:1804-1810.
38. Matsubara K, Kishida S, Matsuura Y, Kitayama H, Noda M, Kikuchi A. Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation. Oncogene 1999;18:1303-12.
39. Ouwens DM, de Ruiter ND, Van Der Zon GC, Carter AP, Schouten J, van der Burgt C, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERKpathway and of Thr69 through RalGDS-Src-p38.EMBOJ 2002;21:3782-93.
40. Wolthuis RM, de Ruiter ND, Cool RH, Bos JL. Stimulation of gene induction and cell growth by the Ras effector Rlf. EMBO J 1997;16: 6748-61.
41. de Ruiter ND, Wolthuis RM, van Dam H, Burgering BM, Bos JL. Rasdependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway. Mol Cell Biol 2000;20:8480-8.
42. Hao Y, Wong R, Feig LA. RalGDS couples growth factor signaling to Akt activation. Mol Cell Biol 2008;28:2851-9.
43. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8.
44. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. RAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 2009;8:834-43.
45. Mahoney CL, Choudhury B, Davies H, Edkins S, Greenman C, Haaften G, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009;100:370-5.
46. Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, et al. Rasinduced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 2010;10:168-75.
47. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.